Education
About Us
Working with TipRanks
Follow Us
Algernon Pharmaceuticals (AGNPF)
OTHER OTC:AGNPF
AGNPF Stock Chart & Stats
$0.05
$0.00(0.00%)
At close: 4:00 PM EST
$0.05
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.03 - $0.08
Previous CloseN/A
Volume93.00
Average Volume (3M)7.73K
Market Cap
$1.54M
Enterprise Value$1.37M
Total Cash (Recent Filing)$210.03K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.40
Next Earnings
May 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding46,499,270
10 Day Avg. Volume2,484
30 Day Avg. Volume7,733
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.77
Price to Sales (P/S)0.00
P/FCF Ratio-1.78
Enterprise Value/Market Cap0.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-16.33
Enterprise Value/Ebitda-0.74
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free balance sheet removes interest obligations and lowers bankruptcy risk, giving management runway to fund clinical programs or pursue partnerships without fixed debt service. This structural strength supports flexibility across funding cycles and clinical timelines.
Narrowing Losses And Improving BurnReported net losses narrowed meaningfully versus earlier years and trailing free cash flow has improved, indicating cost control and execution on expense reduction. Sustained reduction in burn increases the odds the company reaches next clinical milestones with less dilutive financing.
Clinical-stage R&D And Legacy ProductA primary focus on clinical-stage drug development plus ownership of a legacy marketed product provides dual strategic options: advance pipeline or monetize/licence Ifenprodil. This enduring business model supports multiple exit or partnership pathways tied to clinical progress.
Bears Say
No Recurring RevenueZero reported revenue means the business lacks an internal, recurring cash generation engine and remains dependent on trial milestones or external funding. Over months this limits self-sufficiency and heightens execution risk if clinical timelines slip.
Persistent Negative Cash FlowConsistent negative operating and free cash flow forces reliance on capital markets or partners to fund operations. Even with improvement, sustained outflows create ongoing financing needs that can dilute shareholders and constrain long-term planning if not resolved.
Scale And Financing Concentration RiskA one-person employee base and reliance on equity financing signal limited internal scale and execution bandwidth. Structurally, this raises dependency on external partners and recurring capital raises, increasing dilution risk and slowing commercialization or large-scale development progress.
Algernon Pharmaceuticals News
AGNPF FAQ
What was Algernon Pharmaceuticals’s price range in the past 12 months?
Algernon Pharmaceuticals lowest stock price was $0.03 and its highest was $0.08 in the past 12 months.
What is Algernon Pharmaceuticals’s market cap?
Algernon Pharmaceuticals’s market cap is $1.54M.
When is Algernon Pharmaceuticals’s upcoming earnings report date?
Algernon Pharmaceuticals’s upcoming earnings report date is May 05, 2026 which is in 78 days.
How were Algernon Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Algernon Pharmaceuticals overvalued?
According to Wall Street analysts Algernon Pharmaceuticals’s price is currently Overvalued.
Does Algernon Pharmaceuticals pay dividends?
Algernon Pharmaceuticals does not currently pay dividends.
What is Algernon Pharmaceuticals’s EPS estimate?
Algernon Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Algernon Pharmaceuticals have?
Algernon Pharmaceuticals has 46,499,270 shares outstanding.
What happened to Algernon Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Algernon Pharmaceuticals?
Currently, no hedge funds are holding shares in AGNPF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Algernon Pharmaceuticals
Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. It focuses on the areas of nonalcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury associated with COVID-19 in Canada and Australia. The company's lead candidate is NP-120, an N-methyl-d-aspartate (NMDA) receptor glutamate receptor antagonist, which targets NMDA-type subunit 2B (Glu2NB), as well as exhibits agonist activity for the Sigma-1 receptor, a chaperone protein up-regulated during endoplasmic reticulum stress. It is also developing AP-188, a psychedelic compound that is part of the tryptamine family for the treatment of ischemic stroke in humans. Algernon Pharmaceuticals Inc. has an agreement with Charles River Laboratories for preclinical studies of AP-188 for the company's stroke clinical research program. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
Technical Analysis
Appili Therapeutics Inc Class A
―
Rakovina Therapeutics Inc
―
Universal Ibogaine Inc
―
Mindbio Therapeutics Corp.
―
Neural Therapeutics Inc.
―
Ownership Overview
Options Prices
Currently, No data available
---